This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

MorphoSys Future Growth

Future criteria checks 2/6

MorphoSys is forecast to grow earnings and revenue by 59.1% and 25% per annum respectively. EPS is expected to grow by 78.2% per annum. Return on equity is forecast to be 7.7% in 3 years.

Key information

59.1%

Earnings growth rate

78.2%

EPS growth rate

Biotechs earnings growth	42.4%
Revenue growth rate	25.0%
Future return on equity	7.7%
Analyst coverage	Good
Last updated	05 Aug 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:MOR - Analysts future estimates and past financials data (EUR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	425	-78	-120	-50	5
12/31/2025	322	-140	-236	-201	8
12/31/2024	180	-249	-296	-253	3
3/31/2024	241	-469	-286	-284	N/A
12/31/2023	238	-190	-299	-296	N/A
9/30/2023	223	104	-363	-355	N/A
6/30/2023	255	100	-349	-338	N/A
3/31/2023	261	-61	-321	-306	N/A
12/31/2022	278	-151	-382	-367	N/A
9/30/2022	250	-861	-436	-417	N/A
6/30/2022	195	-851	-606	-588	N/A
3/31/2022	174	-596	-610	-583	N/A
12/31/2021	180	-514	-508	-481	N/A
9/30/2021	163	-150	-423	-393	N/A
6/30/2021	143	-103	-295	-246	N/A
3/31/2021	124	-177	-255	-217	N/A
12/31/2020	328	98	-14	35	N/A
9/30/2020	303	64	26	63	N/A
6/30/2020	293	105	98	113	N/A
3/31/2020	309	153	137	152	N/A
12/31/2019	72	-103	-85	-81	N/A
9/30/2019	71	-96	-68	-64	N/A
6/30/2019	114	-42	-42	-39	N/A
3/31/2019	87	-59	-33	-31	N/A
12/31/2018	76	-56	-35	-33	N/A
9/30/2018	94	-27	-16	-14	N/A
6/30/2018	54	-82	-61	-48	N/A
3/31/2018	58	-74	-68	-55	N/A
12/31/2017	67	-70	N/A	-38	N/A
9/30/2017	52	-84	N/A	-52	N/A
6/30/2017	49	-73	N/A	-59	N/A
3/31/2017	49	-68	N/A	-47	N/A
12/31/2016	50	-60	N/A	-47	N/A
9/30/2016	49	-45	N/A	-48	N/A
6/30/2016	48	-40	N/A	-41	N/A
3/31/2016	48	-33	N/A	-35	N/A
12/31/2015	106	15	N/A	-24	N/A
9/30/2015	111	27	N/A	-15	N/A
6/30/2015	116	33	N/A	-3	N/A
3/31/2015	119	37	N/A	-4	N/A
12/31/2014	64	-3	N/A	-14	N/A
9/30/2014	61	-6	N/A	-15	N/A
6/30/2014	60	-5	N/A	79	N/A
3/31/2014	77	7	N/A	76	N/A
12/31/2013	78	7	N/A	89	N/A
9/30/2013	80	14	N/A	100	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MOR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MOR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MOR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MOR's revenue (25% per year) is forecast to grow faster than the German market (5.2% per year).

High Growth Revenue: MOR's revenue (25% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: MOR's Return on Equity is forecast to be low in 3 years time (7.7%).

This company listing is no longer active

MorphoSys Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Price target increased by 13% to €35.50

MorphoSys AG Provides Sales Guidance for the Financial Year 2024

Price target decreased by 8.7% to €31.78

Morphosys AG Provides Earnings Guidance for the Year 2023

Price target increased by 8.0% to €31.61

MorphoSys AG Provides Earnings Guidance for the Year 2023

Recent updates

MorphoSys Completes Voluntary Delisting from the Frankfurt Stock Exchange and Nasdaq Global Market

MorphoSys AG, Annual General Meeting, Aug 27, 2024

MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market

MorphoSys AG to Report Q2, 2024 Results on Aug 29, 2024

MorphoSys AG(XTRA:MOR) dropped from Germany MDAX Index (Performance)

MorphoSys AG(XTRA:MOR) dropped from Germany TECDAX (Total Return) Index

MorphoSys AG Announces Board Changes

Novartis Continues to Progress the Workstreams for Implementation of a Delisting of MorphoSys

Novartis Continues to Progress the Workstreams for Implementation of a Delisting of MorphoSys

New major risk - Negative shareholders equity

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Profitability

Full year 2023 earnings: EPS exceeds analyst expectations

Novartis data42 AG entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG (XTRA:MOR) for €2.3 billion.

Price target increased by 13% to €35.50

Novartis data42 AG entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG (XTRA:MOR) for €2.3 billion.

MorphoSys AG Provides Sales Guidance for the Financial Year 2024

Investor sentiment improves as stock rises 22%

Investor sentiment deteriorates as stock falls 17%

New minor risk - Shareholder dilution

MorphoSys AG to Report First Half, 2024 Results on Aug 07, 2024

MorphoSys AG has filed a Follow-on Equity Offering in the amount of €102.69582 million.

MorphoSys AG to Report Fiscal Year 2023 Results on Mar 13, 2024

MorphoSys AG’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study

Investor sentiment improves as stock rises 30%

New major risk - Share price stability

Price target decreased by 8.7% to €31.78

MorphoSys AG Announces Strong Topline Results from the Phase 3 MANIFEST-2 Study Investigating Pelabresib

New major risk - Financial position

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment deteriorates as stock falls 15%

MorphoSys AG to Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting

Investor sentiment improves as stock rises 15%

Morphosys AG Provides Earnings Guidance for the Year 2023

Zoetis Inc. (NYSE:ZTS) acquired adivo GmbH from founders, High-Tech Gründerfonds, the Swiss Occident Group AG and MorphoSys AG (XTRA:MOR).

Price target increased by 8.0% to €31.61

MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer

MorphoSys AG Provides Earnings Guidance for the Year 2023

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased by 12% to €25.94

Price target increased by 7.3% to €19.64

Morphosys Ag Provides Sales Guidance for the Financial Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 27% to €18.25

MorphoSys AG Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024

Price target decreased to €24.05

MorphoSys AG Announces Sung Lee, Chief Financial Officer Decided to Leave

Price target decreased to €26.50

Morphosys Presents New Longer-Term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity At Ash 2022

MorphoSys AG to Report Q3, 2023 Results on Nov 15, 2023

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to €32.45

MorphoSys AG Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209)

Morphosys Ag Revises Monjuvi U.S. Net Product Sales Guidance for the Full Year of 2022

Price target decreased to €37.06

MorphoSys AG Announces Executive Changes

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Morphosys Ag Updates Monjuvi U.S. Net Product Sales Guidance for the Year 2022

Price target decreased to €40.56

MorphoSys AG Confirms Financial Guidance for the Year 2022

MorphoSys AG Announces Supervisory Board Changes

Price target decreased to €44.67

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts